Paul Wotton's guest appearances

Paul Wotton

Biotech 2050 Podcast

Business Of Biotech

Raman Sehgal

Paul Garofolo

Brian Culley

Caroline Loew

Seth Lederman

David Bates

Jim Sullivan

Tim Sweeney

Tim Miller

Andrew Miller

Leslie Williams

Chris Wright

James Mackay

Atopic Dermatitis

Sarah Howell

OwlTail

On this episode of The Business of Biotech, Obsidian Therapeutics CEO Paul Wotton, Ph.D. takes us behind the scenes to reveal what precipitated the FDA's clearance of its IND application for a novel, engineered tumor-infiltrating lymphocyte therapy called OBX-115.  Learn how the company navigated the regulatory path for a first-of-its-kind biologic therapy developed in partnership with the University of Texas MD Anderson Cancer Center that Dr. Wotton says, should it succeed, will eliminate the patient risk associated with concomitant IL2 therapy and improve clinical outcomes for certain patients with metastatic melanoma. We also get an update on outcomes from Obsidian's unique approach to solving COVID-19 challenges covered on episode 9 of the Business of Biotech.Subscribe to the NEW #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!

On this episode of The Business of Biotech, Obsidian Therapeutics CEO Paul Wotton, Ph.D. takes us behind the scenes to reveal what precipitated the FDA's clearance of its IND application for a novel, engineered tumor-infiltrating lymphocyte therapy called OBX-115.  Learn how the company navigated the regulatory path for a first-of-its-kind biologic therapy developed in partnership with the University of Texas MD Anderson Cancer Center that Dr. Wotton says, should it succeed, will eliminate the patient risk associated with concomitant IL2 therapy and improve clinical outcomes for certain patients with metastatic melanoma. We also get an update on outcomes from Obsidian's unique approach to solving COVID-19 challenges covered on <a href="https://www.bioprocessonline.com/doc/solving-the-covid-workforce-crisis-0001" rel="nofollow" target="_blank">episode 9</a> of the Business of Biotech.Subscribe to the NEW #BusinessofBiotech newsletter at <a href="https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/" rel="nofollow" target="_blank">bioprocessonline.com/bob</a> for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at <a href="https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/" rel="nofollow" target="_blank">bioprocessonline.com/bob</a>!

IND For TIL Therapy With Obsidian Therapeutics' Paul Wotton, Ph.D.

Obsidian Therapeutics CEO Dr. Paul Wotton didn't let pandemic-induced workforce restrictions impede his biopharma's progress. Instead, his team developed a software system purpose-built for biotechs to manage personnel and equipment per ever-changing guidelines. On this episode of The Business Of Biotech: Summer Executive Sessions, Wotton tells us how the application, dubbed SWFT, was built, how it's working, and why Obsidian has made it available to more than 30 (and growing) other biotechs, free of charge. Subscribe to the NEW #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!

<a href="https://obsidiantx.com/" rel="nofollow" target="_blank">Obsidian Therapeutics</a> CEO <a href="https://www.linkedin.com/in/paul-wotton-15246612/" rel="nofollow" target="_blank">Dr. Paul Wotton</a> didn't let pandemic-induced workforce restrictions impede his biopharma's progress. Instead, his team developed a software system purpose-built for biotechs to manage personnel and equipment per ever-changing guidelines. On this episode of The Business Of Biotech: Summer Executive Sessions, Wotton tells us how the application, dubbed SWFT, was built, how it's working, and why Obsidian has made it available to more than 30 (and growing) other biotechs, free of charge. Subscribe to the NEW #BusinessofBiotech newsletter at <a href="https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/" rel="nofollow" target="_blank">bioprocessonline.com/bob</a> for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at <a href="https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/" rel="nofollow" target="_blank">bioprocessonline.com/bob</a>!

Summer Sessions 2: Dr. Paul Wotton Solves A COVID-19 Workforce Crisis

Dr. Paul K. Wotton is the Chief Executive Officer at Obsidian Therapeutics. Obsidian is a biotechnology company pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s proprietary cytoDRiVE™ technology provides a way to control protein degradation using FDA-approved small molecules, permitting precise control of the timing and level of protein expression. The cytoDRiVE™ platform can be applied to design controllable intracellular, membrane and secreted proteins for cell and gene therapies as well as other applications. The Company’s initial applications focus on developing novel cell therapies for the treatment of cancer.Paul has over 30 years of experience in scientific research, product development and corporate growth in the life science industry. Previously, Paul served as Founding President and Chief Executive Officer of Sigilon Therapeutics, Inc. Prior to Sigilon, Dr. Wotton served as President and Chief Executive Officer of Ocata Therapeutics until its acquisition by Astellas Pharma where he was also Co-Chairman of the Office of Integration.In previous roles, Paul has served as President and Chief Executive Officer of Antares Pharma (NASDAQ:ATRS) as well as Chief Executive Officer of Topigen Pharmaceuticals. Dr. Wotton is a named inventor on numerous patents and was the Ernst &amp; Young Entrepreneur of the Year Regional (NJ) Winner Life Sciences in 2014. He serves on the Boards of Directors of Vericel Corporation (NASDAQ: VCEL) and Cynata Therapeutics (ASX: CYP) as its Chairman. Until recently Paul was a board member at Veloxis Pharmaceuticals A/S (Copenhagen: VELO) which was recently acquired by Asahi.  Dr. Wotton holds a B.Pharm (Honors) from UCL, London’s global university, and a Ph.D. in Pharmaceutical Sciences from University of Nottingham.

Dr. Paul K. Wotton is the Chief Executive Officer at Obsidian Therapeutics. Obsidian is a biotechnology company pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s proprietary cytoDRiVE™ technology provides a way to control protein degradation using FDA-approved small molecules, permitting precise control of the timing and level of protein expression. The cytoDRiVE™ platform can be applied to design controllable intracellular, membrane and secreted proteins for cell and gene therapies as well as other applications. The Company’s initial applications focus on developing novel cell therapies for the treatment of cancer. Paul has over 30 years of experience in scientific research, product development and corporate growth in the life science industry. Previously, Paul served as Founding President and Chief Executive Officer of Sigilon Therapeutics, Inc. Prior to Sigilon, Dr. Wotton served as President and Chief Executive Officer of Ocata Therapeutics until its acquisition by Astellas Pharma where he was also Co-Chairman of the Office of Integration. In previous roles, Paul has served as President and Chief Executive Officer of Antares Pharma (NASDAQ:ATRS) as well as Chief Executive Officer of Topigen Pharmaceuticals. Dr. Wotton is a named inventor on numerous patents and was the Ernst &amp; Young Entrepreneur of the Year Regional (NJ) Winner Life Sciences in 2014. He serves on the Boards of Directors of Vericel Corporation (NASDAQ: VCEL) and Cynata Therapeutics (ASX: CYP) as its Chairman. Until recently Paul was a board member at Veloxis Pharmaceuticals A/S (Copenhagen: VELO) which was recently acquired by Asahi. Dr. Wotton holds a B.Pharm (Honors) from UCL, London’s global university, and a Ph.D. in Pharmaceutical Sciences from University of Nottingham.